BACKGROUND: Little is known about cancer surveillance (mammography, clinical breast examination, and pelvic examination) behaviors in long-term (9-16 years) breast cancer survivors. This report describes the relation of these behaviors to demographic and clinical characteristics, psychological symptoms, body satisfaction, and social support. METHODS: Survivors who had participated in Cancer and Leukemia Group B treatment Trial 8541 completed a survey that included questions on breast cancer surveillance and pelvic examination, psychological well being, body satisfaction, and social support. RESULTS: The participation rate was 78% and included 245 breast cancer survivors. Survivors (n = 107; 44%) reported completing breast cancer surveillance (mammography and clinical breast examination) and completing pelvic examination (n = 162; 68%) within recommended guidelines. There were no significant associations between breast cancer surveillance and breast cancer anxiety, depression, stressful life events, body satisfaction, social support, or demographic characteristics. Survivors within recommended guidelines for pelvic examinations were younger (P = .05), married (P = .003), had health insurance (P = .004), and had lower depression scores (P = .005) than survivors who underused or overused pelvic examination. In addition, survivors within recommended pelvic examination guidelines had significantly lower levels of breast cancer anxiety (P = .03) compared with survivors who underused pelvic examination. CONCLUSIONS: Many long-term breast cancer survivors were not within recommended cancer surveillance guidelines. Private health insurance was associated with following recommendations for pelvic examinations, although such a relation did not exist for breast cancer surveillance. The results of this study have implications for the development of educational programs to improve cancer surveillance among the growing population of long-term breast cancer survivors. (c) 2008 American Cancer Society.
BACKGROUND: Little is known about cancer surveillance (mammography, clinical breast examination, and pelvic examination) behaviors in long-term (9-16 years) breast cancer survivors. This report describes the relation of these behaviors to demographic and clinical characteristics, psychological symptoms, body satisfaction, and social support. METHODS: Survivors who had participated in Cancer and Leukemia Group B treatment Trial 8541 completed a survey that included questions on breast cancer surveillance and pelvic examination, psychological well being, body satisfaction, and social support. RESULTS: The participation rate was 78% and included 245 breast cancer survivors. Survivors (n = 107; 44%) reported completing breast cancer surveillance (mammography and clinical breast examination) and completing pelvic examination (n = 162; 68%) within recommended guidelines. There were no significant associations between breast cancer surveillance and breast cancer anxiety, depression, stressful life events, body satisfaction, social support, or demographic characteristics. Survivors within recommended guidelines for pelvic examinations were younger (P = .05), married (P = .003), had health insurance (P = .004), and had lower depression scores (P = .005) than survivors who underused or overused pelvic examination. In addition, survivors within recommended pelvic examination guidelines had significantly lower levels of breast cancer anxiety (P = .03) compared with survivors who underused pelvic examination. CONCLUSIONS: Many long-term breast cancer survivors were not within recommended cancer surveillance guidelines. Private health insurance was associated with following recommendations for pelvic examinations, although such a relation did not exist for breast cancer surveillance. The results of this study have implications for the development of educational programs to improve cancer surveillance among the growing population of long-term breast cancer survivors. (c) 2008 American Cancer Society.
Authors: Maria Gurevich; Gerald M Devins; Christine Wilson; David McCready; Charles R Marmar; Gary M Rodin Journal: Psychosom Med Date: 2004 Jan-Feb Impact factor: 4.312
Authors: Carol P Somkin; Stephen J McPhee; Tung Nguyen; Susan Stewart; Sarah J Shema; Bang Nguyen; Rena Pasick Journal: Med Care Date: 2004-09 Impact factor: 2.983
Authors: J Hsia; E Kemper; C Kiefe; J Zapka; S Sofaer; M Pettinger; D Bowen; M Limacher; L Lillington; E Mason Journal: Prev Med Date: 2000-09 Impact factor: 4.018
Authors: Sara Wilcox; Kelly R Evenson; Aaron Aragaki; Sylvia Wassertheil-Smoller; Charles P Mouton; Barbara Lee Loevinger Journal: Health Psychol Date: 2003-09 Impact factor: 4.267
Authors: Berta M Geller; Karla Kerlikowske; Patricia A Carney; Linn A Abraham; Bonnie C Yankaskas; Stephen H Taplin; Rachel Ballard-Barbash; Mark B Dignan; Robert Rosenberg; Nicole Urban; William E Barlow Journal: Breast Cancer Res Treat Date: 2003-09 Impact factor: 4.872
Authors: Amy K Otto; Emily C Soriano; Scott D Siegel; Stefanie T LoSavio; Jean-Philippe Laurenceau Journal: J Cancer Surviv Date: 2018-10-19 Impact factor: 4.442
Authors: Laura P Forsythe; Neeraj K Arora; Catherine M Alfano; Kathryn E Weaver; Ann S Hamilton; Noreen Aziz; Julia H Rowland Journal: Support Care Cancer Date: 2014-01-12 Impact factor: 3.603
Authors: Jasmin A Tiro; Joanne M Sanders; L Aubree Shay; Caitlin C Murphy; Heidi A Hamann; L Kay Bartholomew; Lara S Savas; Sally W Vernon Journal: Breast Cancer Res Treat Date: 2015-04-29 Impact factor: 4.872
Authors: Laura P Forsythe; Catherine M Alfano; Erin E Kent; Kathryn E Weaver; Keith Bellizzi; Neeraj Arora; Noreen Aziz; Gretchen Keel; Julia H Rowland Journal: Psychooncology Date: 2014-01-30 Impact factor: 3.894
Authors: Melissa Y Carpentier; Jasmin A Tiro; Lara S Savas; L Kay Bartholomew; Trisha V Melhado; Sharon P Coan; Keith E Argenbright; Sally W Vernon Journal: J Cancer Surviv Date: 2012-12-18 Impact factor: 4.442
Authors: Rebecca A Shelby; Cindy D Scipio; Tamara J Somers; Mary Scott Soo; Kevin P Weinfurt; Francis J Keefe Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544